Remove Clinic Remove Nuclear Medicine Remove Radiopharmaceuticals
article thumbnail

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Imaging Technology

announced that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

article thumbnail

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Imaging Technology

milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

article thumbnail

New guidelines cover theranostics for brain tumors

AuntMinnie

The article was published October 10 in the Journal of Nuclear Medicine. These SSTRs can be targeted both with gallium-68 (Ga-68) imaging agents and therapeutic lutetium-177 (Lu-177) radiopharmaceuticals using a so-called theranostics approach.

article thumbnail

Telix acquires assets targeting FAP in nuclear medicine

AuntMinnie

Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine. These were developed by Frank Roesch, PhD, and colleagues at the Institute of Nuclear Chemistry at the Johannes Gutenberg-Universität Mainz, Germany.

article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.

article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. Extravasations Extravasations, in particular, are of interest to the U.S.